Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Swiss Group for Clinical Cancer Research)"
Count: 128
Selected: 0
| NCT ID | Title |
|---|
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | ||
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | ||
| NCT00030732 | Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer | ||
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | ||
| NCT03905343 | Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC | ||
| NCT04630730 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | ||
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC | ||
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | ||
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | ||
| NCT04472949 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | ||
| NCT04245514 | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | ||
| NCT04024475 | Prostate Cancer Biobank | ||
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | ||
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | ||
| NCT03886649 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | ||
| NCT03786198 | Activity Program During Aromatase Inhibitor Therapy | ||
| NCT03762122 | Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) | ||
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | ||
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | ||
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | ||
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma | ||
| NCT03406650 | Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. | ||
| NCT03387917 | TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors | ||
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | ||
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | ||
| NCT02964689 | Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | ||
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | ||
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | ||
| NCT02910843 | Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer | ||
| NCT02877550 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | ||
| NCT02833766 | Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | ||
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | ||
| NCT02597075 | Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy | ||
| NCT02572843 | Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) | ||
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | ||
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | ||
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | ||
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | ||
| NCT02311543 | Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer | ||
| NCT02188537 | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | ||
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | ||
| NCT02058056 | Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC | ||
| NCT02053311 | Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | ||
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | ||
| NCT01954355 | LDE225 and Paclitaxel in Solid Tumors | ||
| NCT01926964 | Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer | ||
| NCT01835236 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | ||
| NCT01718808 | Cetuximab for Elderly Patients With mCRC | ||
| NCT01707966 | Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy | ||
| NCT01593241 | Therapy De-escalation in Seminoma Stage IIA/B |
